• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Progenics Pharmaceuticals

Progenics Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Global Antibody Drug Conjugates (ADC) Market 2017-2022: Analysis By Drugs, Pipeline Drugs, Regulations: Opportunities and Forecasts - Kadcyla Currently Dominates the ADC Market - Research and Markets

    Global Antibody Drug Conjugates (ADC) Market 2017-2022: Analysis By Drugs, Pipeline Drugs, Regulations: Opportunities and Forecasts - Kadcyla Currently Dominates the ADC Market - Research and Markets

  2. UPDATE: These corporate ties will be on display at Scott Gottlieb's FDA commissioner confirmation hearing today

    UPDATE: These corporate ties will be on display at Scott Gottlieb's FDA commissioner confirmation hearing today

  3. It’s Never Too Early: Roth 401(k)s and Other Fun Stuff

    Progenics Pharmaceuticals PGNX announced on March 6 that it would backtrack and reformulate the oral version opioid bowel dysfunction drug MNTX to make it more effective. If successful, the firm could file for its approval in late 2009. Our fair value estimate remains unchanged, as we'd already ...

  4. Investor or Speculator?

    Progenics Pharmaceuticals PGNX and partner Wyeth WYE announced Thursday that both the Food and Drug Administration and the European Medicines Agency have accepted new drug applications for subcutaneous MNTX, which aims to treat postoperative ileus and opioid bowel dysfunction. We are leaving our ...

©2017 Morningstar Advisor. All right reserved.